Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common extranodal lymphoid neoplasm. Chromosomal translocation t(11;18)(q21,q21) is found in 30% of gastric MALT lymphomas and is associated with a failure to respond to standard treatment and a tendency to disseminate. This translocation generates a chimeric protein composed of N-terminal sequences of Inhibitor of Apoptosis 2 (API2, also known as BIRC3 and cIAP2) fused to C-terminal sequences of MALT1. API2-MALT1 promotes cell survival and proliferation via activation of nuclear factor-jB (NF-jB). Here, we investigate the mechanism by which the API2 moiety contributes to NF-jB stimulation. We find that the API2 moiety mediates oligomerization of API2-MALT1 as well as interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2). Surprisingly, oligomerization does not occur via homotypic interaction; rather, the API2 moiety of one monomer interacts with the MALT1 moiety of another monomer. Further, the specific region of the API2 moiety responsible for mediating oligomerization is distinct from that mediating TRAF2 binding. Although deletion or mutation of the TRAF2 binding site does not inhibit oligomerization, it does lead to dramatically decreased NF-jB activation. Deletion of both TRAF2 binding and oligomerization regions results in nearcomplete loss of NF-jB activation. Thus, API2 moietymediated heterotypic oligomerization and TRAF2 binding both contribute to maximal API2-MALT1-dependent NF-jB stimulation.
Introduction
Marginal zone B-cell lymphoma of the mucosaassociated lymphoid tissue (MALT) accounts for 8% of all non-Hodgkin's lymphomas (Zucca et al., 2000) . This tumor arises in extranodal sites that acquire organized lymphoid tissue as a result of chronic inflammation (Zucca et al., 2000) . The stomach is the most common site of MALT lymphoma, where it usually occurs in the setting of chronic Helicobacter pylori (H. pylori) gastritis (Zucca et al., 2000) . The fact that 70% of cases of Stage I gastric MALT lymphoma are cured by eradication of H. pylori with antibiotic therapy suggests that antigenic stimulation plays a role in promoting tumor growth (Isaacson, 1999) . However, in some cases, MALT lymphoma fails to respond to H. pylori eradication, invades the gastric wall and disseminates (Liu et al., 2001b) .
Characterization of recurrent chromosomal translocations in MALT lymphoma has provided important clues into disease pathogenesis. t(1;14)(p22;q32) results in placement of the BCL10 gene adjacent to the strong immunoglobulin heavy-chain locus transcriptional enhancer, leading to deregulated overexpression of Bcl10 (Willis et al., 1999; Zhang et al., 1999) . Similarly, t(14;18)(q32;q21) results in translocation of the MALT1 gene to the immunoglobulin heavy-chain locus and leads to MALT1 overexpression (Murga Penas et al., 2003; Streubel et al., 2003) . Bcl10 and MALT1 form a complex within the cell and synergize in activating the prosurvival transcription factor, nuclear factor-kB (NF-kB) . Bcl10 functions as the upstream regulator in this complex by inducing MALT1 oligomerization, an event that triggers activation of NF-kB through stimulation of the inhibitor of NF-kB kinase (IKK) complex . Extensive genetic and biochemical evidence indicates that Bcl10 and MALT1 operate downstream of the antigen receptor to mediate antigen-dependent activation of NF-kB, which regulates the expression of a variety of genes known to promote lymphocyte survival and proliferation (Lucas et al., 2004) .
A third translocation, t(11;18)(q21;q21), has been identified in 30% of gastric MALT lymphomas (Isaacson and Du, 2004) . This translocation creates a fusion gene that encodes a chimeric protein composed of the N-terminus of API2 (Inhibitor of Apoptosis 2, also referred to as BIRC3 and c-IAP2), linked to the C-terminus of MALT1 (Akagi et al., 1999; Dierlamm et al., 1999; Morgan et al., 1999) . Gastric MALT lymphomas harboring t(11;18) can display distinct adverse clinical features such as advanced stage and resistance to treatment with oral alkylating agents (Liu et al., 2001b; Ye et al., 2003; Iwano et al., 2004; Levy et al., 2005) . In pulmonary MALT lymphoma, t(11; 18) is associated with metastasis to the bone marrow and disease recurrence, and in colorectal MALT lymphoma it is associated with larger tumor size and advanced clinical stage (Remstein et al., 2000; Okabe et al., 2003; Sakugawa et al., 2003) . Interestingly, t(11;18) is associated with failure of gastric MALT lymphoma to respond to H. pylori eradication (Liu et al., 2001a (Liu et al., , 2002 Inagaki et al., 2004) . Taken together, these findings suggest that unlike the majority of cases of MALT lymphoma, tumors expressing API2-MALT1 are not necessarily dependent upon antigenic stimulation for growth and are capable of aggressive patterns of growth and dissemination.
API2 is a member of the inhibitor of apoptosis (IAP) family of proteins, which share a characteristic domain structure that includes one to three baculovirus IAP repeat (BIR) domains in the amino terminal portion of the molecule (Salvesen and Duckett, 2002) (Figure 1a) . IAPs bind to caspases through their BIR-containing Ntermini and are thought to block cell death through inhibition of caspase activity (Deveraux and Reed, 1999; Wright and Duckett, 2005) . The IAP BIR domains also interact with signaling implicated in NF-kB signaling, such as the tumor necrosis factor receptor-associated factor (TRAF) family of adaptor proteins (Deveraux and Reed, 1999; Samuel et al., 2006) . API2-MALT1 fusion transcripts invariably contain the N-terminus of API2 with three intact BIR domains and the C-terminal MALT1 region containing an intact caspase-like domain ( Figure 1a ) (Isaacson and Du, 2004) . This strongly suggests that these specific domains of API2 and MALT1 are critical to the oncogenic activity of the fusion protein.
Unlike wild-type MALT1, which must interact with Bcl10 to activate NF-kB, API2-MALT1 potently stimulates NF-kB in the absence of Bcl10 (Uren et al., 2000; Lucas et al., 2001; Ruland et al., 2003) . This suggests that API2-MALT1 may represent a gain-offunction mutant that promotes lymphomagenesis through inappropriate NF-kB activation. In support of this notion, recent studies show that expression of API2-MALT1 protects cells from apoptosis and promotes proliferation and that NF-kB activation is required for these effects (Hosokawa et al., 2004; Stoffel et al., 2004; Ho et al., 2005) . In this report, we explore the mechanism by which the API2 moiety contributes to API2-MALT1-dependent stimulation of NF-kB. We find that the API2 moiety mediates both oligomerization of the fusion protein and interaction with the TRAF2 adaptor protein. Our data suggest that both of these API2 moiety-mediated interactions contribute to optimal NF-kB activation by API2-MALT1.
Results
The API2 moiety of API2-MALT1 mediates oligomerization via a non-homotypic interaction In the absence of Bcl10, wild-type MALT1 does not activate NF-kB (Uren et al., 2000; Lucas et al., 2001) . It is thought that upon antigenic stimulation, Bcl10 binds Multiple roles for the API2 moiety of API2-MALT1 PC Lucas et al to MALT1 and induces its oligomerization and that enforced oligomerization of the MALT1 C-terminus triggers NF-kB activation Sun et al., 2004) . Because API2-MALT1, unlike wild-type MALT1, potently stimulates NF-kB in the absence of Bcl10 (Uren et al., 2000; Lucas et al., 2001; Ruland et al., 2003) , we wondered whether this oncoprotein might promote lymphocyte proliferation by acting as a 'gain-of-function' mutant of MALT1, which could induce constitutive NF-kB activation via API2 moietymediated oligomerization. To test this hypothesis, we utilized a co-immunoprecipitation assay to determine whether MYC epitope and FLAG-tagged API2-MALT1 proteins interact. We found that unlike wildtype MALT1, which requires co-expression of Bcl10 for oligomerization , API2-MALT1 oligomerizes in the absence of Bcl10 co-expression ( Figure 1b , lane 3). In order to determine whether the API2 moiety mediates this oligomerization, we generated a deletion mutant, API2(1-441), which lacks the MALT1 moiety of API2-MALT1 and retains the N-terminal portion of API2 that is present in 90% of API2-MALT1 fusions ( Figure 1a ) (Isaacson and Du, 2004) . We tested whether this deletion mutant could interact with API2-MALT1 and found that FLAG-API2-MALT1 similarly coimmunoprecipitates with MYC-API2(1-441) (Figure 1b , lane 4). This interaction is specific in that no interaction was observed between API2-MALT1 and control protein, ASC (lane 5). These results support our hypothesis that the API2 moiety mediates API2-MALT1 oligomerization.
We next analysed whether the API2 moiety of one API2-MALT1 monomer mediates oligomerization by forming a homotypic interaction with the API2 moiety of another monomer. To this end, we expressed both FLAG and MYC-tagged versions of API2(1-441) and tested whether they were capable of co-immunoprecipitating. Somewhat surprisingly, we found that although MYC-API2-MALT1 consistently co-immunoprecipitates with FLAG-API2(1-441) (Figure 1c , lane 5), no interaction is observed between MYC-API2(1-441) and FLAG-API2(1-441) (lane 4). We observed similar results when this experiment was carried out in reverse: FLAG-API2(1-441) does not co-immunoprecipitate when MYC-API2(1-441) is used as bait (data not shown). These results suggested for the first time that API2-MALT1 oligomerization does not occur via homotypic interaction between API2 moieties.
A heterotypic interaction between API2 and MALT1 moieties mediates API2-MALT1 oligomerization Because we did not observe a homotypic interaction between API2 moieties, we next tested whether the API2 moiety is capable of interacting with other regions of API2-MALT1, specifically the region corresponding to the MALT1 C-terminus (AA 324-813) (Figure 2a ). This region of MALT1 contains the caspase-like domain and is retained within 100% of cases of the API2-MALT1 fusion protein formed by t(11;18) (Isaacson and Du, 2004) . First, we demonstrated that hemagglutinin (HA)-tagged MALT1(324-813) does co-immunoprecipitate with FLAG-tagged API2(1-441) (Figure 2b , lane 9), whereas fragments corresponding to other regions of MALT1 ((AA 1-139, lane 7) and (AA 1-330, lane 8)) do not interact with API2(1-441). To further confirm that the MALT1 C-terminus (324-813) interacts with the API2 moiety of API2-MALT1, we showed that MYC-API2-MALT1 does bind to FLAG-MALT1(324-813) ( Figure 2c , lane 5), whereas MYC-MALT1(324-813), which lacks the API2 moiety, does not (lane 6). These findings indicate that the MALT1 moiety does not form a homotypic interaction with itself, but it does bind to full-length API2-MALT1 via interaction with the API2 moiety. Taken together, these results strongly support the concept that API2-MALT1 oligomerization is mediated via heterotypic interaction of the API2 and MALT1 moieties.
While this paper was in preparation, another group reported findings that suggest that the BIR1 domain of the API2 moiety is essential to API2-MALT1 oligomerization (Zhou et al., 2005) . In further analysing the heterotypic interaction between API2 and MALT1 moieties, we found that a mutant of API2-MALT1 lacking BIR1 as well as the linker region between BIR1 and BIR2 ( 
Loss of API2-MALT1-dependent NF-kB activity occurs if oligomerization is disrupted
We next sought to analyse whether disruption of oligomerization would result in loss of API2-MALT1-dependent NF-kB activation. We reasoned that if oligomerization is critical, then the API2(1-441) deletion mutant might function as a dominant-negative (DN) mutant to block API2-MALT1-dependent NF-kB activity by competitively inhibiting API2 moiety-mediated oligomerization. Indeed, we found that API2(1-441) dominantly inhibits API2-MALT1-mediated NF-kB activation in a dose-dependent manner ( Figure 3a ). Western blotting demonstrated that inhibition of NF-kB activity is not due to loss of expression of API2-MALT1 (Figure 3a , inset). This effect is specific in that API2(1-441) does not inhibit other activators of NF-kB, including Bcl10 as well as CARMA1, a scaffolding protein that operates upstream of Bcl10 in the NF-kB signaling pathway in lymphocytes (Lucas et al., 2004) (Figure 3a) . Rather, our data suggest that API2(1-441) slightly enhances Bcl10-mediated and CARMA1-mediated NF-kB activation. This finding is consistent with a recent report in which Hu et al. (2006) proposed that the binding of Bcl10 to the BIR region of wild-type API2 leads to Bcl10 ubiquitination and degradation. According to this model, API2(1-441) could competitively inhibit Bcl10 interaction with wildtype API2. Thus, interaction with API2(1-441), which lacks the really interesting new gene (RING) E3 ligase domain, could protect Bcl10 from degradation and therefore enhance CARMA1 and Bcl10-dependent signaling.
To further analyse the contribution of oligomerization to API2-MALT1-dependent NF-kB activation, we compared the ability of wild-type API2-MALT1 to stimulate NF-kB to that of D(1-166)API2-MALT1, which cannot self-oligomerize (see Figure 2d) . We found that D(1-166)API2-MALT1 exhibits near complete loss of NF-kB activation (Figure 3b ). Western blotting (inset) demonstrates that D(1-166)API2-MALT1 is expressed at least as well as full-length API2-MALT1. Thus, the loss of NF-kB activation by D(1-166)API2-MALT1 cannot be attributed to lower expression levels. Together, these results are consistent with the notion that disruption of API2-MALT1 oligomerization is associated with loss of NF-kB activation. However, we have also considered the possibility that overexpression of API2(1-441) and/or deletion of BIR1 might have additional deleterious effects on API2-MALT1 signaling over and above inhibiting oligomerization. It is possible that the BIR1 domain mediates interaction with other signaling proteins that are critical to API2-MALT1-dependent NF-kB activation, and disruption of these interactions may also contribute to loss of NF-kB activity.
In addition to mediating API2-MALT1 oligomerization, the API2 BIR1 also binds to TRAF2 A recent report demonstrated that wild-type API2 binds to TRAF2 through its BIR1 domain and that this interaction greatly enhances TRAF2-mediated NF-kB activation (Samuel et al., 2006) . Like other members of the TRAF family, the C-terminal portion of TRAF2 contains a TRAF-C domain, which mediates binding to members of the TNF receptor superfamily, and a TRAF-N domain, which mediates self-association and association with IAP family members (see Figure 6a ) (Bishop, 2004) . The N-terminal portion of TRAF2 is composed of several zinc finger motifs and a RING domain, which possesses ubiquitin ligase activity and which mediates interactions with proteins that are important for downstream signaling events (Bishop, 2004) . We wondered whether, in addition to mediating oligomerization, the BIR1 domain of API2-MALT1 might also mediate interaction with TRAF2 and whether TRAF2 binding might contribute to API2-MALT1 oncogenic function. To begin to address this possibility, we demonstrated that TRAF2 does bind to API2-MALT1 as predicted from studies of wild-type API2 (Figure 4a TRAF2 binding and oligomerization occur through distinct regions of BIR1 As our data suggest that the BIR1 domain mediates both oligomerization of API2-MALT1 and TRAF2 binding, we next tested whether these two interactions occur through the same region of BIR1. To this end, we generated a series of N-terminal API2-MALT1 deletion mutants ( Figure 5a ) and tested whether these mutants are capable of oligomerization and/or TRAF2 binding. We found that oligomerization occurs through a region between amino acids 49 and 98, which corresponds roughly to the C-terminal two-thirds of BIR1 but excludes the linker region between BIR1 and BIR2. A D1-49 mutant of API2-MALT1 retains the capacity to self-oligomerize (Figure 5b, lane 7) , whereas the D1-98 and D1-166 deletion mutants lose this capacity (lanes 9 and 11). The D1-98 and D1-166 mutants do retain the ability to interact with full-length API2-MALT1 (lanes 8 and 10), which again is consistent with a heterotypic interaction between an intact MALT1 moiety on the deletion mutants and an intact BIR1 domain on the fulllength protein.
Although it retains the capacity to oligomerize, the D1-49 mutant loses the ability to bind to TRAF2, suggesting that TRAF2 binds to a region within AA 1-49 (Figure 5c, lane 6) . This finding also indicates that TRAF2 does not mediate API2-MALT1 oligomerization, because the D1-49 TRAF2 binding-deficient mutant is still capable of self-association. (a) API2 (1-441) dominantly inhibits API2-MALT1-mediated NF-kB activation. API2-MALT1, Bcl10 or CARMA1 were expressed in 293T cells in the presence of increasing amounts of API2(1-441), and NF-kB activity was measured by luciferase reporter assay. Error bars represent standard error of the mean of at least three separate determinations. Western blotting (inset) demonstrates that inhibition of NF-kB activity was not due to loss of expression of API2-MALT1. (b) Deletion of the API2 BIR1 domain is associated with loss of API2-MALT1-mediated NF-kB activation. The 293T cells were transfected with expression constructs encoding full-length API2-MALT1 or D(1-166)API2-MALT1. The resultant NF-kB activity was measured as described above. Error bars represent standard error of the mean of at least three separate determinations. Western blotting with anti-FLAG antibody (inset) demonstrates that the D(1-166)API2-MALT1 deletion mutant is expressed at levels that are comparable to or greater than full-length API2-MALT1.
TRAF2 plays a functional role in API2-MALT1-mediated NF-kB activation
To investigate the contribution of TRAF2 binding to API2-MALT1-mediated NF-kB activation, we analysed the effect of a TRAF2 DN mutant on API2-MALT1 signaling. This mutant lacks the RING domain, which prevents it from transmitting downstream signals (Figure 6a ). We found that the TRAF2DN specifically inhibits API2-MALT1-mediated activation of NF-kB (Figure 6b ), suggesting the possibility that TRAF2 may function downstream of API2-MALT1 in signaling to the IKK complex. We considered the possibility that as TRAF2 binds to BIR1 of API2-MALT1, TRAF2DN may artifactually inhibit API2-MALT1 signaling through steric inhibition of BIR1-mediated oligomerization. If this were the case, we would expect full-length TRAF2 to inhibit API2-MALT1 signaling as well. However, full-length TRAF2 has the opposite effect on API2-MALT1, enhancing its ability to activate NF-kB (Figure 6c) .
We previously demonstrated that enforced oligomerization of the MALT1 moiety of API2-MALT1 results in activation of NF-kB . For these experiments, we constructed an expression plasmid encoding a chimeric protein consisting of three FK506 binding protein (FKBP) dimerization domains, which can be oligomerized by the cell-permeable ligand, AP1510, linked to the C-terminal portion of MALT1 that is retained in the API2-MALT1 fusion. We refer to this chimeric protein as FKBPX3-MALT1(Casp) to indicate that the C-terminal end of MALT1, including the caspase-like domain (Casp), is present in the chimeric protein . In contrast to the effect of the TRAF2DN on API2-MALT1, the Figure 5a for schematic representation of API2-MALT1 deletion mutants), and NF-kB activity was measured using a luciferase reporter assay. Western blotting using anti-FLAG antibody was carried out to assure that mutant proteins were expressed at levels comparable to or greater than wild-type API2-MALT1. Error bars represent standard error of the mean of three separate determinations. (e) Model: API2 moiety mediates heterotypic oligomerization and TRAF2 recruitment through distinct regions of the BIR1 domain, and both interactions contribute to maximal NF-kB stimulation (see Discussion).
TRAF2DN does not inhibit the ability of FKBPX3-MALT1(Casp) to activate NF-kB (Figure 6b ). These findings suggest that the API2-MALT1 fusion protein communicates with NF-kB through TRAF2, whereas the artificially oligomerized MALT1 moiety does not. These results provide the first evidence that the API2-MALT1 fusion protein may promote NF-kB activation through additional mechanisms over and above oligomerization of the MALT1 moiety. In order to further analyse the role of TRAF2 binding in API2-MALT1 signaling, we compared the ability of TRAF2-binding-deficient mutants of API2-MALT1 to activate NF-kB to that of wild-type API2-MALT1. We found that the D1-49 mutant, which lacks the ability to bind to TRAF2, but retains the ability to oligomerize, displays significantly decreased capacity for NF-kB stimulation compared with wild-type API2-MALT1 (Figure 6d ). In addition, we analysed an API2-MALT1 site-directed double mutant in which residues that have been identified as critical for TRAF2 binding to wildtype API2, glutamic acid 47 and arginine 48, are mutated to alanine (Samuel et al., 2006) . The E47A/ R48A double point mutant cannot bind TRAF2 (Samuel et al., 2006) , but retains the capacity to oligomerize (data not shown). Like the D1-49 deletion mutant, E47A/R48A-API2-MALT1 displays significantly decreased NF-kB stimulation (Figure 6d ). The D1-98 and D1-166 deletion mutants of API2-MALT1 lack the TRAF2-binding region and are incapable of oligomerization ( Figure 5 ). These mutants display near complete loss of NF-kB stimulation (Figure 6d ). Western blot analysis was carried out to assure that expression levels of mutant proteins were at least as high as that of wild-type API2-MALT1 (Figure 6d ). Taken together, these data suggest that TRAF2 binding and self-oligomerization, functions that are mediated by distinct subregions of the BIR1 domain of the API2 moiety, both contribute to maximal stimulation of NF-kB by API2-MALT1.
While preparing to submit this work, we became aware of a paper in press, in which the authors demonstrate that API2-MALT1-mediated NF-kB activation is largely retained in TRAF2-deficient mouse embryonic fibroblasts (MEFs) compared with wild-type MEFs, suggesting that TRAF2 might not be required for API2-MALT1-dependent NF-kB activation (Varfolomeev et al., 2006) . However, it is possible that other members of the TRAF family are able to compensate for the absence of TRAF2 in this setting by providing redundant functions. Indeed, it has been frequently reported that TRAF family members display overlapping function. For example, TRAF2 and TRAF6 have redundant roles in mediating NF-kB activation in response to stimulation of the TNFR family member, CD40, in B cells (Hostager et al., 2003; Bishop, 2004) . In order to address the possibility that TRAF2 and TRAF6 serve redundant functions in mediating API2-MALT1-dependent signaling, we tested whether TRAF6 binds to API2-MALT1 and/or operates downstream of API2-MALT1 in activating NF-kB. We found that TRAF6 binds specifically to API2-MALT1 (Supplementary Figure 1a) and that a TRAF6 DN mutant, which lacks the RING domain, specifically blocks API2-MALT1-mediated NF-kB activation (Supplementary Figure 1b) . These results suggest that TRAF6 and TRAF2 could play similar, perhaps redundant, roles in mediated API2-MALT1-dependent signaling.
Discussion
Our data reveal that the API2 moiety of API2-MALT1 mediates at least two interactions that impact NF-kB signaling: self-association and TRAF2 binding (see model, Figure 6e ). Self-association is critical to the pathogenic function of a large number of fusion oncoproteins associated with hematopoietic malignancies, and many investigators are interested in disruption of self association as an attractive target for the rational design of new anticancer therapies (So and Cleary, 2004) . The most well-characterized examples are the tyrosine kinase fusions. In these cases, the signaling properties of the tyrosine kinases are normally regulated by oligomerization, such as that induced by ligand binding to cell surface receptors. However, an acquired oncogenic chromosomal translocation can create a fusion oncoprotein in which a tyrosine kinase domain is inappropriately oligomerized by virtue of its fusion to a heterologous protein partner containing a dimerization domain. The breakpoint cluster region-Abelson tyrosine kinase (BCR-ABL) prior to fusion found in chronic myelogenous leukemia and the nucleophosminanaplastic lymphoma kinase (NPM-ALK) fusion found in anaplastic large cell lymphoma represent two such examples. The ABL or ALK kinase domains are inappropriately dimerized via fusion to BCR or NPM, respectively, resulting in downstream signaling dysregulation (Turner and Alexander, 2006) . A second group of fusion oncoproteins that are activated via self-association are the chimeric transcription factors seen in acute leukemias. In these cases, it is thought that enforced oligomerization of transcription factors results in altered DNA-binding properties and changes in protein partner affinities (So and Cleary, 2004) . Chimeric fusion oncoproteins containing the DNA-binding domains of the retinoic acid receptor-a in acute promyelocytic leukemia or the mixed lineage leukemia protein in infant leukemias are prominent examples (So and Cleary, 2004) . Our data now suggest that API2-MALT1 should be added to the growing list of fusion oncoproteins that can perturb intracellular signaling and promote oncogenesis via inappropriate self-association.
We demonstrate for the first time that the API2 moiety of API2-MALT1 promotes oligomerization of the fusion protein via heterotypic, rather than homotypic interaction. That is, we have demonstrated that the API2 moiety is not capable of interacting with itself, but instead, it interacts with the C-terminal portion of the MALT1 moiety (Figure 2 ; see also model, Figure 6e ). This finding is consistent with previous analysis that revealed that wild-type API2 does not homo-oligomerize (Rothe et al., 1995) . In our own studies, we have also verified that wild-type API2 does not homo-oligomerize nor does it bind the API2(1-441) deletion mutant, which contains only the API2 moiety of API2-MALT1 (data not shown). Heterotypic self-association is a phenomenon that has been reported to occur in other fusion oncoproteins. For example, a recent report demonstrated that the AML1/(MDS1/EVI1) (AME) fusion oncoprotein, which is produced by the t(3;21)(q26;q22) chromosomal translocation associated with acute myeloid leukemia, self associates via a complex heterotypic mechanism. Specifically, the Runt domain of the AML1 moiety binds to the distal zinc finger of the MDS/EVI1 moiety, and this interaction is required for oncogenic activity (Senyuk et al., 2005) . Hopefully, future analyses will elucidate the number of monomers present within the oligomerized API2-MALT1 complex as well as the precise arrangement of the various functional domains of API2 and MALT1. In our model (Figure 6e) , we show the MALT1 caspase-like domains of each monomer being brought into proximity to one another in a head-to-tail arrangement within the center of a dimerized complex, but other arrangements are also possible.
We have identified amino acids 49-98 as the region of the API2 moiety that is required for oligomerization of API2-MALT1 to occur. This region encompasses the C-terminal two-thirds of the BIR1 domain, which contains the conserved CX 2 CX 16 HX 6À8 C motif capable of coordinating a zinc ion. This conserved 'zinc-finger' structure underlies the surface groove where caspases bind to IAP BIR domains (Luque et al., 2002) . It is tempting to speculate that this zinc finger may mediate oligomerization by interacting in some way with the caspase-like domain of the MALT1 moiety. More detailed structural analyses of this region of the API2 moiety may shed light on the specific molecular interactions responsible for API2-MALT1 self-association. Disruption of this interaction could represent a novel treatment modality for refractory MALT lymphoma associated with t(11;18).
The mechanism by which self-association of API2-MALT1 might perturb NF-kB signaling and contribute to oncogenesis is not entirely clear. Based on our previous work, enforced oligomerization of the MALT1 C-terminus results in constitutive activation of NF-kB ). The precise mechanism by which the oligomerized MALT1 C-terminus communicates with NF-kB is an area of considerable controversy. Zhou et al. (2004 Zhou et al. ( , 2005 suggest that MALT1 possesses E3 ubiquitin ligase activity and that, together with the Ubc13/MMS2 E2 enzyme complex, MALT1 directly catalyses ubiquitination of NF-kB essential modulator (NEMO), the regulatory subunit of the IKK complex, upon oligomerization. Other groups suggest that MALT1 oligomerization triggers TRAF6-dependent ubiquitination of NEMO (Sun et al., 2004; Dong et al., 2006) . Further studies are required to resolve this controversy.
Our data suggest that the binding of TRAF2 to the API2 BIR1 domain also contributes to dysregulated NF-kB signaling by API2-MALT1. Perhaps the most intriguing finding is that the TRAF2 DN mutant, which lacks the RING/ubiquitin ligase domain, inhibits API2-MALT1-dependent NF-kB signaling, but does not affect NF-kB signaling by artificially oligomerized MALT1. These findings suggest that API2-MALT1 does not activate NF-kB solely by mimicking the oligomerization of the MALT1 C-terminus, but that API2-MALT1 possesses additional means of communicating with NF-kB, namely through BIR1-mediated interaction with TRAF2. To support this notion, we demonstrated that both the D1-49 deletion mutant and the E47A/R48A site directed mutant of API2-MALT1, which retain the ability to oligomerize but lose the ability to bind to TRAF2, display significantly decreased NF-kB activation compared with wild-type API2-MALT1. In contrast, the D1-98 and D1-166 deletion mutants, which cannot bind TRAF2 or self-associate, display near complete loss of NF-kB activation. In addition to disrupting TRAF2 binding and/or oligomerization, deletions or mutations of the BIR1 domain might also disrupt other vital functions of the API2 moiety of API2-MALT1. For example, a recent report suggested that the BIR1 domain of API2 might contribute to API2-MALT1-dependent NF-kB activation by promoting association of the fusion protein with membrane lipid rafts (Baens et al., 2006) . Another recent report demonstrated that the API2 BIR1 interacts with Bcl10 (Hu et al., 2006) . These authors suggested that binding of API2-MALT1 to Bcl10 may promote lymphocyte proliferation by protecting Bcl10 from wild-type API2-mediated ubiquitination and degradation (Hu et al., 2006) . Further studies are needed to assess the relative contribution of BIR1-mediated oligomerization, TRAF2 binding, lipid raft association and Bcl10 binding to API2-MALT1 oncogenic function.
In summary, clinical studies suggest that unlike the majority of cases of MALT lymphoma, tumors expressing API2-MALT1 are not necessarily dependent upon antigenic stimulation for growth and are capable of aggressive patterns of growth and dissemination. Thus, it is imperative that we gain an understanding of the precise molecular mechanisms by which API2-MALT1 functions to promote lymphomagenesis. Several recent studies have shown that expression of API2-MALT1 protects cells from apoptosis and promotes proliferation and that NF-kB activation is required for these effects (Hosokawa et al., 2004; Stoffel et al., 2004; Ho et al., 2005) . Our studies demonstrate for the first time that the API2 moiety mediates oligomerization of API2-MALT1 via heterotypic interaction of the BIR1 domain with the MALT1 moiety. Further, we demonstrate that a region composed of AA 1-49 of the API2 moiety of API2-MALT1 mediates binding to TRAF2. Our results suggest that BIR1-mediated heterotypic oligomerization and TRAF2 binding both contribute to maximal NF-kB signaling. We hypothesize that self-association and TRAF2 recruitment allow for API2-MALT1 to potently and constitutively activate NF-kB in the absence of upstream regulatory signals. Such activity would promote the proliferation of API2-MALT1 expressing
